Integrated biomarkers and cardiac phenotypes associated with atrial fibrillation: evidence from real-world hospital data
-
By
-
Xuli Chen
-
Yanxi Ning
-
Yuxiang Wang
-
Yuelin Hu
-
Yanchao Liu
-
Wenwen Xiao
-
May 15, 2026
-
Clinical Scorecard: Biomarkers and Cardiac Characteristics Linked to Atrial Fibrillation: Insights from Real-World Hospital Data
At a Glance
| Category | Detail |
|---|
| Condition | Atrial Fibrillation (AF) |
| Key Mechanisms | Association between B-type natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) |
| Target Population | Hospitalized patients with complete data on BNP and LVEF |
| Care Setting | Hospital-based observational study |
Key Highlights
- 45.6% of hospitalized patients had atrial fibrillation.
- Higher BNP/LVEF values are independently associated with increased AF risk.
- BNP/LVEF demonstrated good discriminatory ability for AF (AUC = 0.84).
- Significant non-linear association between BNP/LVEF and AF risk.
- Subgroup analysis showed heterogeneity across sex, smoking, alcohol consumption, and coronary heart disease.
Guideline-Based Recommendations
Diagnosis
- AF diagnosed based on cardiac rhythm recordings or physician diagnosis.
Management
- Consider BNP/LVEF ratio for risk stratification in AF.
Monitoring & Follow-up
- Monitor BNP levels and LVEF as part of routine clinical evaluation.
Risks
- AF is associated with increased risk of stroke, heart failure, and all-cause mortality.
Patient & Prescribing Data
270 hospitalized patients with complete data on BNP and LVEF.
BNP/LVEF may provide clinically useful information for AF risk stratification.
Clinical Best Practices
- Integrate BNP and LVEF measurements for enhanced cardiac risk assessment.
- Utilize echocardiographic indices alongside biomarkers for comprehensive evaluation.
Related Resources & Content
